Cancer remains one of the leading causes of death worldwide, responsible for over 8 million deaths in 2015. While treatments for cancer have vastly improved over the past few decades, new and more effective anticancer therapies are still greatly needed. Researchers around the world are working tirelessly to better understand the underlying causes and mechanisms of cancer, with the hope of developing novel approaches for prevention, diagnosis and treatment. This paper will provide an overview of some of the most promising areas of anticancer research today.
Cancer stem cell research aims to target the small population of cells within a tumor that have stem cell-like properties and drive tumor growth, relapse and metastasis. By developing therapies that can specifically target and eliminate cancer stem cells, recurrence rates may be reduced and survival improved. Researchers are working to better characterize the genes and pathways that allow cancer stem cells to self-renew and differentiate abnormally. Experimental therapies targeting cancer stem cell signaling pathways and mechanisms of self-renewal are showing promise in preclinical studies.
Immunotherapy is revolutionizing cancer treatment by harnessing the power of a patient’s own immune system. Checkpoint inhibitors, which block inhibitory checkpoints like PD-1 and CTLA-4 that cancers use to evade immune detection, have shown durable responses in certain cancers like melanoma. CAR T-cell therapy, which genetically engineers a patient’s T-cells to recognize and attack cancer cells, has achieved complete remission in some leukemias and lymphomas. Emerging immune cell therapies utilize other immune cell types, like natural killer or dendritic cells. Combination therapies pairing immunotherapy with chemotherapy, radiation or targeted therapies aim to further boost anticancer immune responses.
Targeted therapies that interfere with specific molecular changes or pathways driving cancer growth and progression are also a major focus of research. These include small-molecule inhibitors of signaling pathways frequently altered in cancer like the MAPK pathway in melanoma and NSCLC. Monoclonal antibodies targeting tumor-associated antigens or growth factor receptors have shown promise, like cetuximab against EGFR in colorectal cancer. Combining multiple targeted agents that hit cancer at different points in key pathways may improve outcomes versus single agents. New genome engineering techniques are identifying novel targets.
Extensive research on cancer genomics and epigenetics aims to achieve a more comprehensive understanding of cancer at the molecular level. Large-scale projects are underway to profile thousands of tumor genomes across cancer types. This promises to uncover cancer driver mutations, epigenetic abnormalities and biomarkers that can guide therapeutic development and precision medicine approaches tailored to a patient’s individual tumor profile. Integrating multi-omics datasets encompassing genomics, proteomics and metabolomics holds potential to derive deeper insights.
Tumor microenvironment research investigates how stromal and immune cells that infiltrate the cancer influence tumor growth, progression and therapeutic responses. Interactions between cancer cells and components in their microenvironment like fibroblasts, blood vessels and the extracellular matrix help cancers evade destruction. Therapies targeting these interactions or modulating the tumor microenvironment to activate antitumor immunity offer new strategies.
One promising approach involves blocking the signals cancers use to induce angiogenesis, the formation of new blood vessels that supply nutrients and enable metastasis. Agents inhibiting the vascular endothelial growth factor (VEGF) pathway, which cancers hijack to stimulate angiogenesis, have shown benefit in cancers like renal cell carcinoma. Another area of research aims to normalize abnormal tumor blood vessels using agents like angiopoietin inhibitors to boost drug delivery and efficacy.
Combined modality treatments integrating anticancer agents with established modalities like surgery, radiotherapy and hyperthermia show synergy in experimental models. Ongoing clinical research evaluates integrating immunotherapy, targeted therapy, epigenetic modifiers and other experimental agents with surgery and radiotherapy to boost local and systemic disease control via abscopal effects. Advances in proton beam therapy, stereotactic body radiation therapy and image-guided radiation promise to improve therapeutic indices. Other physical approaches like high-intensity focused ultrasound show promise in preclinical research for directly killing cancer cells or sensitizing them to drugs.
Developing new imaging modalities that can non-invasively monitor treatment responses in real-time, detect metastasis early and guide surgery holds the potential to significantly impact patient outcomes. Novel molecular imaging and nanoparticle-based imaging agents tailored to specific processes in cancer aim to provide early assessment of treatment efficacy for individualized therapy management. Integration of imaging and liquid biopsy techniques like circulating tumor DNA assessment may one day enable truly personalized, adaptive treatment protocols.
With further discoveries from this diverse, multi-pronged research, progress is being made towards overcoming cancer. Though challenges remain, ongoing advances in biological understanding, screening, early detection, precise therapy and survivorship care offer hope that more effective prevention and management of this disease can be realized in the future. A combination of innovative basic science and carefully designed clinical studies will be crucial to translating the discoveries of today into meaningful benefits for cancer patients in the years to come.
Andrew Stroud